ACADEMIC SUPPORT SERVICES AGREEMENT

AGREEMENT NUMBER: 21-8568

This agreement is entered into between the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison’s Carbone Cancer Center (hereafter University) and the The Medical College of Wisconsin, Inc. (hereafter Contractor or MCW):

CONTRACTOR INFORMATION

Contractor’s Name (as shown on W9): The Medical College of Wisconsin, Inc.
Address: 8701 Watertown Plank Road Hub 5386
City / State / Zip: Milwaukee, WI 53226
Contact Name / E-Mail: Jon B. Mayer / jmayer@mcw.edu

CONTRACT TERM

Start Date: December 1, 2020
End Date: November 30, 2022

COMPENSATION INFORMATION

Fee not to exceed (total amount to be paid for the full contract term) $ 150,000.00
- Indirects not permitted.
- Fee will be paid on the purchase order.

PAYMENT TERMS: (NOTE: Payment will be made 30 days upon receipt of an invoice from the Contractor. Contractor must invoice according to the terms of the contract.)

The University will transfer fees to Contractor in one payment upon execution of this contract and receipt of invoice.

DEPARTMENT CONTACT INFORMATION

Name: Mark McClintock
Telephone: 608-262-3925
E-mail: mrmccllin@wisc.edu
The University’s collaboration with Contractor is part of the University’s Centene Pancreas Cancer Collaborative program. MCW’s clinical and basic science research with pancreas cancer includes senior investigators, Susan Tsai, MD and Douglas Evans, MD. MCW pancreas cancer research program includes additional investigators, including William Hall, MD, a radiation oncologist, Mandana Kamgar, a medical oncologist who are both developing investigator-initiated trials, and two basic scientists, Dr. Subramaniam Malarkannan, PhD, a cancer immunologist, and Dr. Jong-In Park, PhD, who is an expert in signaling and cancer metabolism. The funds from the Centene Pancreas Cancer Collaborative will be used to support ongoing translational research from the Park and Malarkannan lab. Work from Dr. Park’s lab will further develop preclinical data on the efficacy of combinatorial therapy using tyrosine kinase inhibitors and metabolic targeting agents, such as Mito-Q. Work from Dr. Malarkannan’s lab be focused on immunologic changes in the tumor microenvironment related with radiation therapy. Additional funds, if available, may be utilized to develop investigator-initiated trials in pancreatic cancer.

Evaluation of Progress Funded projects will compete for funds for each subsequent year. Future funding is dependent on progress, funds available, and scientific priorities. By design, these are higher risk than average projects. We anticipate that a project may exit this funding mechanism based on its success or failure. Graduation of a successful project, as measured by achieving substantial external funding, is the preferred exit strategy. Experimental evidence that a concept is not feasible or failure of a project to make progress despite good faith effort are acceptable termination criteria for a given project.

Overall Deliverables and Metrics Standard Benchmarks of scientific productivity will help measure the success or failure of the existing projects and the collaborative science including scientific publications, impact of those publications, external or internal grant funding. Deliverables from this research award include:

- Final written summary and progress report after one year from start.
- Presentation to UWCCC Pancreas Cancer Research Collaborative.
- Participation in UWCCC led strategic planning for pancreas cancer research in WI.
- Dr. Susan Tsai is an Advisory Committee Member of Pancreas Cancer Centene Collaborative and will work with UWCCC Advisory members (Dr. Howard Bailey is acting Chair) to create a 5-year strategic plan.
DEBARMENT

Federal Executive Order (E.O.) 12549 “Debarment” requires that all contractors receiving individual awards, using federal funds, and all subrecipients certify that the organization and its principals are not debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal department or agency from doing business with the Federal Government. By signing this document you certify that your organization and its principals are not debarred. Failure to comply or attempts to edit this language may disqualify your bid. Information on debarment is available at the following websites: www.sam.gov and https://acquisition.gov/far/index.html see section 52.209-6.

Your signature certifies that neither you nor your principal is presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any federal department or agency.

SUPPLIER DIVERSITY

Minority, Women Owned, and Service Disabled Veteran Owned businesses are encouraged to register for State of Wisconsin certified status by going to the following website and following the instructions that are provided there: http://www.doa.state.wi.us/Divisions/Enterprise-Operations/Supplier-Diversity-Program

For Federal Small Business Administration (SBA) status pertaining to small, disadvantaged, veteran owned, service disabled, woman owned, or HUBZone business designations please visit: https://www.sba.gov/contracting/getting-started-contractor/make-sure-you-meet-sba-size-standards

CONTRACTOR ACCEPTANCE

I agree to the standard terms and conditions attached to this agreement. I verify that I am duly qualified and willing to perform the services as an independent contractor. The fees under this Agreement do not exceed my normal and customary rate. I am not a current University of Wisconsin System employee.

FOR THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM

University of Wisconsin-Madison

Lori Voss

Director of Purchasing
UW Madison Division of Business Services
6/1/2021

FOR THE CONTRACTOR

The Medical College of Wisconsin, Inc.

April A. Haverty, MPE, JD

Name Printed or Typed

Director, Grants and Contracts

Title

4/30/2021

Phone Number

Agreement No: 21-8568